Evaluation of allogeneic Transplantation in Patients above the age of 60 years with High Risk Acute Myeloid Leukemia (ETAL-2)
Kriterien zur Bestimmung der zweckmäßigen Vergleichstherapie und Recherche und Synopse der Evidenz zur Bestimmung der zweckmä
Kriterien zur Bestimmung der zweckmäßigen Vergleichstherapie und Recherche und Synopse der Evidenz zur Bestimmung der zweckmä
MATRIX / High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS ly
Evaluation of allogeneic Transplantation in Patients above the age of 60 years with High Risk Acute Myeloid Leukemia (ETAL-2)
Evaluation of allogeneic Transplantation in Patients above the age of 60 years with High Risk Acute Myeloid Leukemia (ETAL-2)
![The Use of Phospholipids to Make Pharmaceutical Form Line Extensions - Hoogevest - 2021 - European Journal of Lipid Science and Technology - Wiley Online Library The Use of Phospholipids to Make Pharmaceutical Form Line Extensions - Hoogevest - 2021 - European Journal of Lipid Science and Technology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d5077a12-1cab-4370-b574-7b84426ab76e/ejlt202000297-fig-0001-m.jpg)